Post Approval Study to Assure the ContInued saFety and effectIveness of Neuro Cochlear Implant System in Adult Users

Sensorineural Hearing Loss, Bilateral Clinical Trial

— PACIFIC  

Official title:

Post Approval Study to Assure the ContInued saFety and effectIveness of Neuro Cochlear Implant System in Adult Users

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05154188
• Other study ID #: CIP25
• Status: Not yet recruiting
• Start date: September 1, 2025
• Est. completion date: February 2029

Study information

• Verified date: March 2024
• Source: Oticon Medical
• Contact: Michel HOEN, PHD
• Phone: +33679191047
• Email: MHOE[@]oticonmedical.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

On June 23, 2021, the Oticon Medical Neuro Cochlear Implant System (NCIS) was granted premarket approval (PMA) in the US to treat individuals 18 years or older, with bilateral severe-to-profound sensorineural hearing loss, who obtain limited benefit from appropriately fitted hearing aid(s).

To help assure the continued safety and effectiveness of an approved device, a post-approval study was required as a condition of approval under 21 CFR 814.82(a)(2).

The purpose of this study is to provide longer-term data on the safety and effectiveness of the Neuro Cochlear Implant System under general conditions of use in the postmarket environment.

Description:

The post-approval study will be an open-label, prospective, multi-center, single-arm, non-randomized, self-controlled clinical trial in 10 clinical sites in the US.

The purpose of this study is to provide longer-term data on the safety and effectiveness of the Neuro Cochlear Implant System under general conditions of use in the postmarket environment. This study will be conducted as a prospective, non-controlled, non-randomized study in 10 clinical sites.

A total of 60 subjects, newly treated will be enrolled. Study subjects will be followed for 3 years post implantation of the device with a target follow-up rate of 80% at the end of the study

The primary safety endpoint is the comparison of the type and frequency of adverse events and serious adverse events observed during the study period. The effectiveness endpoints will include the within-subject differences for sentence recognition as evaluated with the AzBio test.

The study will include the following visits: baseline, 1-month post-surgery (activation date), 3 months, 6-months, 12-months, 18-months, 24-months, and 36-months post-activation. Each participant will serve as their own control with baseline measurements.

The total estimated duration of the study is 60 months: 24 months of recruitment and 36 months of subject participation.

The first patient is expected to be included within 6 months of study approval (obtained on August 19, 2021).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: February 2029
• Est. primary completion date: February 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Individuals 18 years of age or older

• Obtain limited benefit from appropriately fitted hearing aids

• Bilateral severe-to-profound sensorineural hearing loss _ Severe-to-profound hearing loss is determined by a pure-tone average (PTA) superior or equal (=) to 70 dB HL at 500, 1000 and 2000 Hz. Limited benefit from amplification is defined by scores of 50% or less on a validated sentence recognition test in quiet (AzBio sentences), in the best-aided listening condition _

Exclusion Criteria:

• Previous cochlear implantation

• Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array

• Active external or middle ear infections or tympanic membrane perforation in the ear to be implanted

• Presence of medical contraindications to middle-ear or inner-ear surgery or anesthesia as required

• Diagnosis of retro-cochlear pathology

• Diagnosis of auditory neuropathy

• Unrealistic expectations on the part of the subject regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure and use of the prosthetic device

• Unwillingness or inability to comply with all investigational requirements

• Additional cognitive, medical, or social handicaps that would prevent completion of all study requirements

Related Conditions & MeSH terms

• Deafness
• Hearing Loss
• Hearing Loss, Bilateral
• Hearing Loss, Sensorineural
• Sensorineural Hearing Loss, Bilateral

Intervention

Device:
• Neuro Cochlear Implant system
Patients will be regular candidates for a cochlear implantation surgery, according to the indication criteria of the Neuro Cochlear Implant System and the device will be used according to its intended purpose

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Oticon Medical

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stability of improvement of speech perception performance at 12- and 36-months post-activation with AzBio sentence scores.	Average scores for AzBio sentence tests will be recorded in Quiet at 12- and 36-months post-activation and compared to pre-operative (baseline) measures.; The AzBio sentence test is a validated sentence recognition test in quiet and has a score range of 0-100% with higher values indicating better scores.	At 12- and 36-months post-activation (visit 9 and visit 11)
Primary	Safety outcome	Occurrence and severity of all adverse events and serious adverse events occuring during the study period. All device failures (internal and external parts) will be documented.	From Visit 1(8- 12 weeks pre-surgery) to Visit 12 (36 Months post-activation)
Secondary	Stability of improvement of speech perception performance at 12- and 36-months post-activation with CNC-words scores.	Consonant-Nucleus-Consonant (CNC) scores will be recorded in Quiet at 12- and 36-months post-activation and compared to pre-operative (baseline) measures.; The CNC word test has a score range of 0-100% with higher values indicating better scores.	At 12- and 36-months post-activation (visit 9 & visit 12)
Secondary	Stability of outcomes over time using AzBio Sentence scores at 1 month in Quiet.	Scores for AzBio sentence tests will be recorded in Quiet at 1-month post-activation in quiet and compared to pre-operative (baseline) measures.; The AzBio sentence test is a validated sentence recognition test in quiet and has a score range of 0-100% with higher values indicating better scores.	At 1 month post-activation (Visit 6)
Secondary	Stability of outcomes over time using AzBio sentences in Quiet and Noise at 3- ; 6- and 24-months post-activation	Average scores for AzBio sentence tests will be recorded in Quiet at 3- ; 6- and 24-months post-activation and compared to pre-operative (baseline) measures.; The AzBio sentence test is a validated sentence recognition test and has a score range of 0-100% with higher values indicating better scores.	at 3 months(visit 7), 6 months (visit 9) and 24 months (visit 11)
Secondary	Stability of outcomes over time using CNC word scores at 3-, 6- and 24-months	Average scores for CNC word test will be recorded at 3-, 6- and 24 months post-activation and compared to pre-operative (baseline) measures.; The Consonant-Nucleus-Consonant (CNC) word test has a score range of 0-100% with higher values indicating better scores.	At 3 months(visit 7), 6 months (visit 9) and 24 months (visit 11)
Secondary	Stability of outcomes over time for patients under a bimodal condition (i.e., patient wearing a contralateral hearing aid).	Average scores for AzBio sentence tests will be recorded in Noise (at +10dB SNR), at 3- and 12-months post-activation and compared to pre-operative (baseline) measures.; The AzBio sentence test is a validated sentence recognition test and has a score range of 0-100% with higher values indicating better scores.	At 3-months post activation (visit 7) and 12 months (visit 9)
Secondary	Longitudinal measures of patient reported outcomes in a newly-implanted population	Patient reported outcome (PRO) measures including quality of life, listening effort and tinnitus at 6-,12-,24- and 36 months post-activation	At 6-,12-,24- and 36 months post-activation (Visits 8,9,11,12)
Secondary	Longitudinal measures of cognitive abilities in a newly implanted population	Scores on a cognitive assessment at 12-24 and 36 months post-activation	At 12-24 and 36 months post-activation (Visits 9,11,12)
Secondary	Longitudinal programming parameters (T- and C- levels)	T and C levels collected at all intervals	At activation (Visit 5), then from 3 months post-activation (V7) throught study completion (an average of 3 years post activation)
Secondary	Longitudinal device functionality measures (impedances)	Electrode impedances collected at all intervals	At activation (Visit 5), then from 3 months post-activation (V7) throught study completion (an average of 3 years post activation)
Secondary	Pedictors of outcomes: Electrode impedances collected at all intervals	Electrode impedances collected at all intervals	At surgery visit (Visit 3 baseline visit) then from activation, 1-month post surgery( visit 5) throught study completion (an average of 3 years post activation)
Secondary	Pedictors of outcomes: eCAP responses collected in the operating room	eCAP responses collected in the operating room	From activation (visit 5) throught study completion (an average of 3 years post activation)
Secondary	Proportion of major postsurgical complications and AEs over time	Surgeon perception of handling of the Neuro Zti and electrode array as well as information related to surgical technique	At surgery visit (i.e. visit 3, baseline visit, )